Clinical Trial

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)

Study acronym: HTLP-ONCO
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-11 -> 2027-06 2026-08-13
minor Completion pushed: 2028-08 -> 2029-02 2026-08-13
Trial Details
NCT Number NCT04707300
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Hematologic Malignancy
Enrollment 10 participants
Start Date 2022-02-16
Primary Completion 2027-06 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-12